Molecular target drug side effect skin rash improving agent

A vitamin C derivative-based agent provides a safe and cost-effective solution to suppress skin eruptions from molecular target drugs, particularly on the face and upper back, outperforming existing treatments.

JP2024166821APending Publication Date: 2024-11-29FUJITA HEALTH UNIVERSITY +1
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
JP2023083192
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-19
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Current methods for addressing skin eruptions caused by molecular target drugs, such as anti-EGFR drugs, are inadequate in providing sufficient improvement and are often costly and reliant on antibiotics.

Method used

An agent containing a vitamin C derivative, specifically sodium L-ascorbyl phosphate, is applied topically to suppress skin eruptions, offering a safe, low-cost alternative without antibiotics.

Benefits of technology

The agent effectively reduces skin eruptions on the face and upper back caused by molecular target drugs, demonstrating significant improvement in a majority of subjects with minimal side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024166821000001_ABST
    Figure 2024166821000001_ABST
Patent Text Reader

Abstract

To provide a molecular target drug side effect skin rash improving agent that can effectively suppress skin rashes as a side effect from the use of molecular target drugs without depending on antibiotics, in simple, safe, and low-cost manners.SOLUTION: A molecular target drug side effect skin rash improving agent contains a vitamin C derivative (for example, sodium L-ascorbyl phosphate) as an active ingredient. This can suppress skin rashes as a side effect from the use of molecular target drugs without depending on antibiotics, in simple, safe, and low-cost manners.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an agent for improving skin rash caused by a side effect of a molecular targeted drug, and in particular to an agent that is designed to effectively suppress skin rash caused by a side effect of a molecular targeted drug in a simple, safe, and low-cost manner without relying on antibiotics. [Background technology]

[0002] Chemotherapy for cancer is a general term for treatment methods that aim to suppress or destroy the growth of cancer cells by using specific drugs called antitumor agents (e.g., cytotoxic drugs, molecular targeted drugs, hormone drugs, etc.). When administered, chemotherapy agents travel throughout the body and attack cancer cells present in the body, so they can be expected to have a progressive effect of destroying cancer cells wherever they are.

[0003] However, chemotherapy drugs sometimes cause side effects such as fatigue and malaise, such as "dullness," "easily fatigued," "lack of energy," "feeling heavy," "unable to concentrate on things," "stomatitis," "diarrhea, back pain," "nausea, vomiting, loss of appetite," etc. These side effects significantly reduce the quality of life (QOL) of patients undergoing treatment.

[0004] Among them, dermatitis is one of the side effects that is directly linked to the decline of QOL. Chemotherapeutic agents that cause dermatitis include fluorouracil drugs (Xeloda (registered trademark), TS-1 (registered trademark), etc.), cytotoxic drugs such as taxane drugs, anti-EGFR drugs (Erbitux (registered trademark), Vectibix (registered trademark)), "molecular targeted drugs" classified as Multiple TKI (Stivarga (registered trademark), Sutent (registered trademark), Nexavar (registered trademark)), and "immune checkpoint inhibitors" such as anti-PD-1 antibodies (Opdivo (registered trademark), Keytruda (registered trademark)).

[0005] In particular, skin eruptions that occur as a side effect when using "molecular targeted drugs" often affect the entire body, causing acne-like eruptions and fat embolisms on the face, neck, and upper back, as well as inflammation around these lesions. Paronychia and pyogenic granulomas are also characteristic of the fingertips. Furthermore, in cases of long-term administration, dryness may spread throughout the body, accompanied by itching. The state is shown in the photographs of Figures 3 to 9.

[0006] Figure 3 is a frontal photograph showing a skin rash as a side effect when an anti-EGFR drug is administered, Figure 4 is an enlarged photograph of a part (chin) of the photograph in Figure 3, Figure 5 is a photograph from the back, Figure 6 is an enlarged photograph of a part (back) of Figure 5, Figure 7 is a photograph of the fingers, Figure 8 is a photograph of both feet, and Figure 9 is an enlarged photograph of a part (toes) of Figure 8. Acne-like skin rash is observed in all of them.

[0007] Reported measures to combat this include oral administration of tetracycline antibiotics (Minomycin (registered trademark)), oral administration of macrolide antibiotics (Rurid (registered trademark)), frequent face washing (so-called acne treatment), and the use of moisturizers and topical steroids during dry periods, but it is difficult to say at present that these methods are sufficiently effective in preventing or improving the condition.

[0008] Specifically, the incidence rate of acne-like skin rash of grade 2 or higher was 24% in 35 cases in which anti-EGFR drugs were used in 2011 and 2012. Even in large-scale clinical trials reported to date, the incidence rate has been around 19% to 40%, suggesting that current countermeasures are not effective.

[0009] Incidentally, examples of prior art documents that describe the reduction of side effects caused by administration of molecular targeted drugs include Patent Documents 1 and 2. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] JP 2020-147501 A [Patent Document 2] JP 2019-48850 A Summary of the Invention [Problem to be solved by the invention]

[0011] The above conventional configuration has the following problems. In other words, to treat the skin rash that is a side effect of administering anti-EGFR drugs, methods such as taking oral tetracycline antibiotics (Minomycin (registered trademark)), taking oral macrolide antibiotics (Rurid (registered trademark)), washing the face frequently (so-called acne treatment), and using moisturizers and topical steroids during dry periods have been tried, but there was a problem in that these methods did not provide sufficient improvement. This is also true when other molecular targeted drugs are used.

[0012] The present invention has been made based on these points, and its object is to provide a molecular targeted drug side effect skin rash ameliorator that can effectively suppress skin rash caused by side effects of the use of molecular targeted drugs in a simple, safe, and low-cost manner without relying on antibiotics. [Means for solving the problem]

[0013] In order to achieve the above object, the molecular targeted drug side effect skin rash improving agent according to claim 1 of the present invention is characterized by containing a vitamin C derivative as an active ingredient. Furthermore, the molecular targeted drug side effect skin rash improvement agent according to claim 2 is a molecular targeted drug side effect skin rash improvement agent according to claim 1, characterized in that it is used to improve a molecular targeted drug side effect skin rash that has occurred on the skin above the upper back. Furthermore, the molecular targeted drug side effect skin rash improving agent according to claim 3 is characterized in that the molecular targeted drug side effect skin rash improving agent according to claim 2 is used to improve molecular targeted drug side effect skin rash that has occurred on the face. The molecular targeted drug side effect skin rash improving agent according to claim 4 is characterized in that the molecular targeted drug side effect skin rash improving agent according to claim 1 contains 3% by weight or more of a vitamin C derivative. The molecular targeted drug side effect skin rash improving agent according to claim 5 is characterized in that the molecular targeted drug side effect skin rash improving agent according to claim 4 contains 5% by weight or more of a vitamin C derivative. The molecular targeted drug side effect skin rash improving agent according to claim 6 is characterized in that the molecular targeted drug side effect skin rash improving agent according to claim 5 contains 5% by weight of a vitamin C derivative. Furthermore, the molecular targeted drug side effect skin rash improving agent according to claim 7 is characterized in that in the molecular targeted drug side effect skin rash improving agent according to claim 1, the vitamin C derivative is sodium L-ascorbyl phosphate. Furthermore, the molecular targeted drug side effect skin rash improving agent according to claim 8 is characterized in that in the molecular targeted drug side effect skin rash improving agent according to claim 1, the molecular targeted drug is an anti-EGFR drug. Effect of the Invention

[0014] As described above, the molecular targeted drug side effect skin rash improving agent according to claim 1 of the present invention contains a vitamin C derivative as an active ingredient, so that it can suppress skin rash, a side effect caused by the use of molecular targeted drugs, simply, safely, and at low cost without relying on antibiotics. Furthermore, according to the molecular targeted drug side effect skin rash improving agent of claim 2, the molecular targeted drug side effect skin rash improving agent of claim 1 is used to improve a molecular targeted drug side effect skin rash that has occurred on the skin above the upper back, so that it is possible to suppress the skin rash, which is a side effect caused by the use of molecular targeted drugs, simply, safely, and at low cost without relying on antibiotics. Furthermore, according to the molecular targeted drug side effect skin rash improving agent of claim 3, the molecular targeted drug side effect skin rash improving agent of claim 2 is used to improve a molecular targeted drug side effect skin rash that has occurred on the face, so that it is possible to suppress the skin rash, which is a side effect caused by the use of a molecular targeted drug, simply, safely, and at low cost without relying on antibiotics. Furthermore, according to the molecular targeted drug side effect skin rash improving agent of claim 4, the molecular targeted drug side effect skin rash improving agent of claim 1 contains 3% by weight or more of a vitamin C derivative, so that skin rash, which is a side effect caused by the use of molecular targeted drugs, can be suppressed simply, safely, and at low cost without relying on antibiotics. Furthermore, according to the molecular targeted drug side effect skin rash improving agent of claim 5, the molecular targeted drug side effect skin rash improving agent of claim 4 contains 5% by weight or more of a vitamin C derivative, so that skin rash, which is a side effect caused by the use of molecular targeted drugs, can be suppressed simply, safely, and at low cost without relying on antibiotics. In addition, according to the molecular targeted drug side effect skin rash improving agent of claim 6, the molecular targeted drug side effect skin rash improving agent of claim 5 contains 5% by weight of vitamin C derivative, so that skin rash, which is a side effect caused by the use of molecular targeted drugs, can be suppressed simply, safely, and at low cost without relying on antibiotics. Furthermore, according to the molecular targeted drug side effect skin rash improving agent of claim 6, in the molecular targeted drug side effect skin rash improving agent described in claim 1, the vitamin C derivative is sodium L-ascorbyl phosphate, so that the skin rash, which is a side effect caused by the use of molecular targeted drugs, can be suppressed simply, safely, and at low cost without relying on antibiotics. Furthermore, according to the molecular targeted drug side effect skin rash improving agent of claim 7, in the molecular targeted drug side effect skin rash improving agent of claim 1, the molecular targeted drug is an anti-EGFR drug, so that the skin rash, which is a side effect caused by the use of the molecular targeted drug, can be suppressed simply, safely, and at low cost without relying on antibiotics. [Brief description of the drawings]

[0015] [Figure 1]1A and 1B are photographs showing Example 1 of the first embodiment of the present invention, in which FIG. 1(a) is a photograph showing the state before an improvement agent is prescribed, and FIG. 1(b) is a photograph showing the state after an improvement agent is prescribed. [Diagram 2] 2(a) is a photograph showing the condition before the prescription of an improvement agent, FIG. 2(b) is a photograph showing the condition after the prescription of an improvement agent, and FIG. 2(c) is a photograph showing the condition after the prescription of an improvement agent. [Diagram 3] This is a frontal photograph showing skin rash as a side effect when administering an anti-EGFR drug. [Figure 4] 4 is a photograph showing an enlarged view of a part (jaw portion) of FIG. 3. [Diagram 5] This is a photograph taken from the back showing skin rash as a side effect when an anti-EGFR drug was administered. [Figure 6] 6 is a photograph showing an enlarged view of a part (back) of FIG. 5. [Figure 7] This is a photograph of a fingertip showing a skin rash as a side effect of administering an anti-EGFR drug. [Figure 8] These are photographs of both legs showing skin rash as a side effect of administering an anti-EGFR drug. [Figure 9] 9 is a photograph showing an enlarged view of a part (right toes) of FIG. 8. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] A first embodiment of the present invention will be described below with reference to FIGS. The molecular targeted drug side effect skin rash improving agent according to the first embodiment is an aqueous solution of sodium L-ascorbyl phosphate, which is a derivative of vitamin C. By applying the molecular targeted drug side effect skin rash improving agent to the affected area, the skin rash caused by the side effect of the molecular targeted drug is improved.

[0017] Vitamin C derivatives are a general term for processed products that have been improved from vitamin C (L-ascorbic acid). Vitamin C derivatives solve the problems that vitamin C has, namely, its unstable molecular structure that easily breaks, its low absorption by the skin, and its dryness, and are approved as food additives and quasi-drugs, and are widely used as an active whitening ingredient.

[0018] Sodium L-ascorbyl phosphate is a type of vitamin C derivative, and is used in cosmetics and quasi-drugs (active ingredient: skin whitening). It has excellent radical scavenging properties that remove active oxygen caused by ultraviolet rays, etc., and improves serious skin damage such as acne, wounds, and burns. Vitamin C also promotes collagen synthesis, helping to restore skin changes caused by various stresses and aging. Although vitamin C derivatives have been reported to be effective in resolving various skin problems, there have been no reports of their preventive or ameliorative effects on skin inflammation accompanied by skin rashes that occur when chemotherapy drugs, especially molecular targeted drugs, are used.

[0019] In addition to the above-mentioned sodium L-ascorbyl phosphate, examples of vitamin C derivatives include magnesium ascorbyl phosphate, trisodium ascorbyl palmitate phosphate, sodium ascorbate phosphate, aminoprolyl ascorbate phosphate, ascorbyl glucoside, ascorbyl palmitate, ascorbyl stearate, sodium ascorbyl sulfate, sodium ascorbyl phosphate, and trisodium ascorbyl palmitate phosphate.

[0020] The content of the vitamin C derivative in this embodiment is, for example, 5.0% by weight based on the total amount of the composition.

[0021] The dosage form of the pharmaceuticals, quasi-drugs, and cosmetics containing the molecular targeted drug side effect skin rash improving agent according to this embodiment is not particularly limited as long as it does not impair the effects of the present invention. For example, any dosage form used for external skin preparations such as sprays, ointments, lotions, and creams can be applied. The base used for these external skin preparations is not particularly limited, and may be any known or newly provided one. For example, petrolatum, castor oil, silicone, squalane, sodium acrylate, behenyl alcohol, glycerol monostearate, stearyl alcohol, ethanol, batyl alcohol, phenoxyethanol, 1,3-butylene glycol, isopropyl myristate, stearic acid, lecithin, and purified water can be used alone or in combination of two or more.

[0022] In addition to the above-mentioned base components, the molecular targeted drug side effect skin rash improving agent of the present invention can appropriately contain various components acceptable for producing pharmaceuticals, quasi-drugs, and cosmetics, i.e., additives such as antioxidants, preservatives, humectants, thickeners, buffers, adsorbents, solvents, emulsifiers, and stabilizers, within a range that does not impair the effects of the present invention.

[0023] As described above, the present invention is a skin rash improvement agent that contains a vitamin C derivative as an active ingredient. Vitamin C derivatives are not pharmaceutical ingredients, but are also ingredients that are commonly used in cosmetics, health foods, and general foods, and therefore are highly safe. Furthermore, as an external preparation for the skin, it can be used simply by applying it to the affected area. It is not effective against inflammation around the nails, but it is effective in improving skin eruptions, mainly around the face, neck, and upper back.

[0024] The first embodiment will now be described in detail with reference to examples. However, the present invention is not limited to these examples. In the following examples, percentages (%) are by weight unless otherwise specified. EXAMPLES

[0025] A first embodiment will be described. EXAMPLES

[0026] Formulation example 1 of the molecular targeted drug side effect skin rash improvement agent used in the test is shown below. The units are the amounts (wt%) in the formulation per 100 ml. (Prescription Example 1) (Ingredients) (Weight%) Propanediol 5.0 Glycerin 2.0 Sodium L-ascorbyl phosphate (Vitamin C derivative) 5.0 Purified water remainder The preparation method was to add and dissolve predetermined amounts of propanediol, glycerin, and sodium L-ascorbyl phosphate in a predetermined amount of purified water.

[0027] Formulation Example 1 contains 5.0% by weight of sodium L-ascorbyl phosphate. The amount of sodium L-ascorbyl phosphate is preferably 3.0% by weight or more, more preferably 5.0% by weight or more. The upper limit is about 10% by weight. If the amount exceeds 10% by weight, there is a problem in terms of solubility.

[0028] In Formulation Example 1, the vitamin C derivative L-ascorbyl phosphate sodium was used as "Ascorbic Acid PS" manufactured by Showa Denko K.K., the propanediol was used as "Zemer Select Propanediol" manufactured by DuPont Co., Ltd., and the glycerin was used as "Concentrated Glycerin for Cosmetics" manufactured by Sakamoto Yakuhin Kogyo Co., Ltd. Furthermore, tap water or groundwater filtered through a membrane filter was used as purified water.

[0029] This section explains the evaluation of the degree of skin side effects of molecular targeted drugs. The degree of skin rash was evaluated by modifying the "Grade for Acne Skin Lesions" in the CTCAE (Common Terminology Criteria for Adverse Events) version 4.0 (May, 2009), which summarizes the side effects of anticancer drugs, in a form specialized for evaluating lesions that have been treated with topical agents containing vitamin C derivatives. The evaluation criteria are described below.

[0030] First, the evaluation of the face will be described. Excellent: The area of ​​the rash at the application site is reduced by 20% or more before and after the test, and a clear reduction in redness is confirmed in 20% or more of the areas. Good: The area of ​​the rash at the application site is reduced by 10% or more before and after the test, and a clear reduction in redness is confirmed in 10% or more of the areas. Slight improvement (Fair): The area of ​​the rash at the application site is reduced by 10% or less before and after the test, and a clear reduction in redness is confirmed in 10% or less of the areas. No Effect: There was no change in the area of ​​the rash at the application site before and after the test, and no clear reduction in redness was observed. Poor: The area of ​​rash and redness of the applied area worsened before and after the test.

[0031] Next, the evaluation of the nail surrounding area of ​​the fingertip will be described. Excellent: Complete disappearance of paronychia Good: Disappearance of subjective pain due to reduction in inflammation around the nail Fair: Spontaneous relief of pain due to reduction in periungual inflammation No Effect: Pain and inflammation remain Poor

[0032] In this Example 1, subjects who showed improvement after the end of application (Excellent+Good+Fair) were determined to be subjects who showed improvement, and the improvement rate (%) was calculated using the following formula. Improvement rate (%) = {(number of subjects who showed improvement) / (number of subjects used in the test)} x 100

[0033] In this Example 1, the solution shown in Prescription Example 1 was filled into a spray bottle and applied to the affected area in one push at a volume of 2 to 3 ml, 3 to 5 times a day, to 9 subjects who had used an anti-EGFR drug, and the effects were examined after 2 to 8 weeks.

[0034] The evaluation results of Formulation Example 1 are shown in Table 1. [Table 1]

[0035] As shown in Table 1, the efficacy was examined in nine subjects who used anti-EGFR drugs (two of whom withdrew from the drug). The subjects were administered anti-EGFR as follows. Merck Biopharmaceuticals' cetuximab (Erbitux®) and Takeda Pharmaceutical's Panitumumab (Pectibix®) were used as anti-EGFR. The administration method was intravenous drip injection, and the dosage was 250 ng / m2 weekly for cetuximab (Erbitux®) and 6 ng / kg weekly for Panitumumab (Pectibix®). The administration period was continued as long as the effect lasted. When the topical preparation described in Formulation Example 1 was used, the condition of the face showed a 66.67% improvement from before to after application. On the other hand, inflammation around the nails of the feet and fingers did not show any improvement (0%).

[0036] Examples of characteristic improvements in the face are shown in Figures 1 and 2. Figure 1(a) is a facial photograph of one subject before the treatment with an improvement agent, and Figure 1(b) is a facial photograph after the treatment with an improvement agent. Similarly, Figure 2(a) is a facial photograph of another subject before the treatment with an improvement agent, and Figures 2(b) and 2(c) are facial photographs after the treatment with an improvement agent. These photographs confirm that inflammation in the face has improved.

[0037] As described above, according to this embodiment, the following effects can be obtained. First, an aqueous solution of sodium L-ascorbyl phosphate can improve skin rashes, particularly facial rashes, caused by side effects of molecular targeted drugs. Furthermore, sodium L-ascorbyl phosphate is not a pharmaceutical ingredient, but is an ingredient that is commonly used in cosmetics, health foods, and general foods, making it low-cost and reducing adverse effects such as side effects on the skin. In this embodiment, sodium L-ascorbyl phosphate has been taken as an example of the vitamin C derivative, but the improving effect can also be expected with other vitamin C derivatives.

[0038] The present invention is not limited to the first embodiment. First, in Example 1 of the first embodiment, sodium L-ascorbyl phosphate is used as an example of the vitamin C derivative, but the present invention can be applied to other vitamin C derivatives in the same manner. In Example 1 of the first embodiment, sodium L-ascorbyl phosphate was used as the vitamin C derivative at 5.0% by weight, but the present invention is not limited to this. In addition, in Example 1 of the first embodiment, sodium L-ascorbyl phosphate is given as an example of the vitamin C derivative, and propanediol and glycerin are used, but the present invention is not limited to this. Additionally, the first embodiment described above is merely one example. [Industrial Applicability]

[0039] The present invention relates to an agent for improving skin rash caused by a side effect of a molecular targeted drug, and in particular to an agent that can effectively suppress skin rash caused by a side effect of a molecular targeted drug simply, safely, and at low cost without relying on antibiotics, and is suitable, for example, as an agent for improving skin rash for patients administered an anti-EGFR drug.

Claims

1. An agent for improving skin rash, a side effect of a molecular targeted drug, characterized by containing a vitamin C derivative as an active ingredient.

2. The agent for improving skin rash caused by a side effect of a molecular targeted drug according to claim 1, A molecular targeted drug side effect skin rash improving agent, characterized in that it is used to improve a molecular targeted drug side effect skin rash that has occurred on the skin above the upper back.

3. The agent for improving skin rash caused by a side effect of a molecular targeted drug according to claim 2, A molecular targeted drug side effect skin rash improving agent, characterized in that it is used to improve a molecular targeted drug side effect skin rash that has occurred on the face.

4. The agent for improving skin rash caused by a side effect of a molecular targeted drug according to claim 1, An agent for improving skin rash, a side effect of a molecular targeted drug, characterized by containing 3% by weight or more of a vitamin C derivative.

5. The agent for improving skin rash caused by a side effect of a molecular targeted drug according to claim 4, An agent for improving skin rash, a side effect of a molecular targeted drug, characterized by containing 5% by weight or more of a vitamin C derivative.

6. The agent for improving skin rash caused by a side effect of a molecular targeted drug according to claim 5, An agent for improving skin rash, a side effect of a molecular targeted drug, characterized by containing 5% by weight of a vitamin C derivative.

7. The agent for improving skin rash caused by a side effect of a molecular targeted drug according to claim 1, A skin rash improvement agent as a side effect of a molecular targeted drug, characterized in that the vitamin C derivative is sodium L-ascorbyl phosphate.

8. The agent for improving skin rash caused by a side effect of a molecular targeted drug according to claim 1, An agent for improving skin rash, a side effect of a molecular targeted drug, wherein the molecular targeted drug is an anti-EGFR drug.

Citation Information

Patent Citations

  • Skin preparation for external use in drug intoxication dermatitis

    JP1997012456A

  • Skin care preparation containing ascorbic acids

    JP2002145751A

  • Skin care treatment external preparation for atopic dermatitis and various xeroderma and rough skin diseases

    JP2003055191A

  • Health injury inhibitor

    JP2006248917A

  • Vitamin K for prevention and treatment of rashes secondary to anti-egfr therapy

    JP2008536865A